Clinical Data BMS brings the buzz around late-stage readouts amid a so-so Q1 Pharmaceutical TechnologyBMS is awaiting Phase III readouts from potential Eliquis successor, milvexian and schizophrenia med, Cobenfy, expected later this year.Read full story pharminent May 1, 2026 (Last updated: May 1, 2026) Pharmaceutical Technology BMS is awaiting Phase III readouts from potential Eliquis successor, milvexian and schizophrenia med, Cobenfy, expected later this year. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Where Gross-to-net Pressure Actually Lives After LaunchNext: Eli Lilly lifts 2026 revenue guidance as Q1 marks dominant opening Related Stories Clinical Data Parkinson’s drug from Biogen, Denali comes up short pharminent May 22, 2026 Clinical Data Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival pharminent May 22, 2026 Clinical Data Lilly’s triple agonist shows bariatric surgery-like weight loss results pharminent May 21, 2026
